OmniAb(US:OABI)2024-08-10 15:29Business Growth and Partnerships - Active partners reached 83 as of June 30, 2024, with a 30% growth over the last 24 months[6, 7] - Two new platform license agreements were signed in Q2 2024 with DAAN Bio and Topaz Therapeutics[6] - The company's partners are globally distributed, with 58% in North America, 22% in Europe, and 20% in Asia as of June 30, 2024[9] - The company supports a growing range of new antibody formats as part of its innovation plans[11, 13] Program Development and Milestones - Active programs increased to 333 as of June 30, 2024, net of attrition[10] - There are 32 active clinical programs and approved products as of June 30, 2024[12] - Preclinical and later-stage programs have grown 39% over the last 24 months[11] - Licenses for current active programs have significant future milestone potential, with >$3 billion for antibody programs and ̴$700 million for small molecule ion channel programs[22] Financial Performance - Total revenues for Q2 2024 were $7.6 million, compared to $6.9 million in Q2 2023[26] - Net loss for Q2 2024 was $(13.6) million, compared to $(14.7) million in Q2 2023[26] - Cash and investments were $57.2 million as of June 30, 2024, compared to $87.0 million as of December 31, 2023[28]